Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
NEW YORK, March 19, 2018 -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Schmidt, Ph.D. will join the firm in June as a Senior Analyst and Senior Managing Director in a planned expansion of the firm’s Healthcare Research team. Dr. Schmidt will focus on the coverage of Biotech companies, working closely with our growing therapeutics team.
Dr. Schmidt will join Guggenheim from LEERINK Partners, where he has been an equity research analyst since 2009 and was named runner-up in the 2017 Institutional Investor All-America Research Survey in the Biotech/Mid- & Small-Cap category. Previous to joining LEERINK in 2009, he was a healthcare analyst and consultant for Susquehanna International Group’s private equity team. Dr. Schmidt was a research fellow at Harvard University previous to his work at Susquehanna.
“We are excited to have Michael join our growing healthcare equity research team,” said Stefano Natella, Director of Equity Research. “He represents an important next step in our plan to invest substantially in our research capabilities, particularly in the healthcare sector. We look forward to his continued success at Guggenheim.”
Michael Schmidt received his Ph.D. and M.Sc. from the University of Stuttgart in biochemistry and molecular genetics, respectively.
About Guggenheim Securities
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at [email protected] or 212.518.9200.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $305 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1Assets under management are as of 12.31.2017 and include consulting services for clients whose assets are valued at approximately $66bn.
Media Contact
Ellen Cunningham
Guggenheim Partners
212.518.9578
[email protected]
